Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas, Drais Partner To Develop Compound | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Astellas, Drais Partner To Develop Compound

Seldar to take over development activities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Astellas Pharma and Drais Pharmaceuticals have entered into a partnership to develop and commercialize ASP7147, a bombesin BB2 receptor antagonist for the treatment of irritable bowel syndrome with diarrhea. Astellas will transfer ownership of the drug to Seldar Pharma, Inc., a virtual company that will be operated by Drais’ executive team. Astellas and Drais entered into a similar agreement in April to advance ASP3291 through another virtual company, Telsar, which will also be operated by Drais.

Seldar will be responsible for all development, manufacturing and commercialization activities and the associated costs. Astellas is entitled to receive a milestone payment and royalties on future sales. Astellas also has the right of first exclusive negotiation for future partnering activities related to ASP7147 and the right of first refusal for the Japanese market as well as non-exclusive negotiation for other markets.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics